The Cell Factory is a full subsidiary business unitcompany of Esperite Group (Euronext: ESP). Esperite is, listed at Euronext Amsterdam and Paris. Esperite is a leading international company in biobanking, regenerative and predictive medicine since 2000.
The Cell Factory fully owns a patent family on broad applications of MSC-derived EVs and exosomes in treatment of various inflammatory diseases.
The Cell Factory is part of the Esperite group with over 10 years of experience in stem cells biobanking.
Access to Esperite’s build-for-purpose lab facilities (GMP/GLP) in Belgium and other Esperite’s international resources: legal, financial, regulatory, HR, marketing, logistics, IT.
The company has full rights for commercialization of the new IPs generated in the research projects sponsored by Esperite.
The Cell Factory has developed a proprietary production process of the highest quality stem cells and EVs with low and competitive production costs – production process is GMP-compliant (ISO/GLP) and ready for technology transfer and scale-up production.
One manufacturing process can be used for production of stem cells and EVs for multiple applications and different therapeutic targets.
Esperite and The Cell Factory have built an international network of the leading academic teams and clinical partners supporting pre-clinical research and clinical translation.
The Cell Factory’s staff are experienced scientists (PhD), medical professionals (MD) and technicians (MSc, BSc).
Billions-worth market of stem cell therapies (ARM annual data report 2015) is largely using stromal/mesenchymal stem cells (MSC), with over 500 clinical trials worldwide. In most of the applications, the immunomodulatory and trophic capabilities of MSC are utilized.
It has been demonstrated that EVs secreted by MSC have similar immunomodulatory potential as the origin cells and can be used instead of MSC in therapy. Esperite’s The Cell Factory fully owns the patents family which covers EVs applications in treatment of all autoimmune, chronic and acute inflammatory diseases (among others):
The Cell Factory strategy of clinical product development and clinical translation:
Key focus of the EVs product development:
This approach will significantly increase the clinical and commercial success of the EVs product and reduce the development time and cost.
Moreover, this strategy will pave a way for the new EVs products, which are currently developing for other indications in neuro-inflammatory diseases and beyond.
We expect that an investment in development of clinical applications of autologous perinatal stem cells (cord blood and cord tissue) will have a significant impact on CryoSave biobanking business in the near future. Investments in autologous advanced therapies using perinatal cells will benefit with broader offer of experimental therapies available for the clients in a long-term.
The main advantage of perinatal stem cells is their young age and genetic and epigenetic quality. These make autologous perinatal stem cells a unique starting material for new technologies in regenerative medicine e.g. tissue engineering and cell reprogramming. The key advantages of perinatal cells, when comparing to the cells derived from adults are:
i) low level of genetic mutations accumulating in the lifetime,
ii) easier and more efficient reprogramming process,
iii) less epigenetic changes accumulating in the lifetime,
iv) faster and more efficient cell expansion.